Prot #CS1-003: A Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of 3 Doses of CS1 in Subjects with Pulmonary Arterial Hypertension

Project: Research project

Project Details

StatusActive
Effective start/end date12/7/2212/7/25

Funding

  • Worldwide Clinical Trials, Inc. (Prot #CS1-003 // Prot #CS1-003)
  • Cereno Scientific AB (Prot #CS1-003 // Prot #CS1-003)